MedTrace Logo

Accelerated PrEP Access for Black MSM and TW

NCT04329442 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-05-19

No results posted yet for this study

Summary

The investigators will pilot-test an accelerated PrEP initiation approach among young high-risk Black/African American (B/AA) men who have sex with men (MSM) and transgender women (YMSM/TW) at the point of care in community contexts.

Conditions

Interventions

DRUG

Emtricitabine / Tenofovir Disoproxil Oral Tablet

30 day supply of 200mg tablets

Sponsors & Collaborators

  • Planned Parenthood Great Plains

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Darnell N Motley, PhD · University of Chicago

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2021-07-31
Completion
2021-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329442 on ClinicalTrials.gov